相似文献
1
HIV prevention transformed: the new prevention research agenda.
Lancet. 2011 Jul 16;378(9787):269-78. doi: 10.1016/S0140-6736(11)60877-5.
2
Neglected tropical diseases and the HIV prevention agenda.
Lancet. 2011 Dec 17;378(9809):2069-70. doi: 10.1016/S0140-6736(11)61897-7.
3
Perspectives on HIV prevention: priorities for a new era.
J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S255-9. doi: 10.1097/QAI.0b013e318298b973.
4
Toward an AIDS-free generation.
JAMA. 2012 Jul 25;308(4):343-4. doi: 10.1001/jama.2012.8142.
5
Separate goals, converging priorities: on the ethics of treatment as prevention.
Dev World Bioeth. 2013 Aug;13(2):57-62. doi: 10.1111/dewb.12021. Epub 2013 Jun 25.
6
From modeling to morals: imagining the future of HIV PREP in Lesotho.
Dev World Bioeth. 2013 Aug;13(2):70-8. doi: 10.1111/dewb.12029. Epub 2013 Jun 25.
7
Anti-retrovirals for treatment and prevention--time for new paradigms in our response to the HIV/AIDS epidemic?
Dev World Bioeth. 2013 Aug;13(2):ii-iii. doi: 10.1111/dewb.12033.
8
[HIV/AIDS: the new therapeutic strategies remain a priority].
Rev Med Suisse. 2009 Nov 11;5(225):2301-2.
9
Ethical use of antiretroviral resources for HIV prevention in resource poor settings.
Dev World Bioeth. 2013 Aug;13(2):79-86. doi: 10.1111/dewb.12022. Epub 2013 May 31.
10
Joining forces.
Nature. 2010 Jul 15;466(7304):S9-10. doi: 10.1038/nature09239.
引用本文的文献
1
Challenges of integrating HIV prevention and treatment in China's border mountain regions: a grounded theory study.
BMC Infect Dis. 2025 May 9;25(1):687. doi: 10.1186/s12879-025-11087-y.
2
Developing a Practice-Driven Taxonomy of Implementation Strategies for HIV Prevention.
J Acquir Immune Defic Syndr. 2025 Apr 1;98(4):377-385. doi: 10.1097/QAI.0000000000003581. Epub 2025 Feb 19.
3
Cohort profile: Rahima Moosa Mother and Child Hospital maternal HIV cohort, Johannesburg, South Africa.
BMJ Open. 2024 Sep 20;14(9):e085082. doi: 10.1136/bmjopen-2024-085082.
4
"If you find that I am HIV positive, don't tell me": Exploring the barriers and recommendations for HIV prevention services utilization among youth in rural southwestern Uganda.
PLOS Glob Public Health. 2024 Sep 13;4(9):e0002555. doi: 10.1371/journal.pgph.0002555. eCollection 2024.
5
Safe sex negotiation and HIV risk reduction among women: A cross-sectional analysis of Burkina Faso 2021 Demographic and Health Survey.
PLOS Glob Public Health. 2024 Apr 24;4(4):e0003134. doi: 10.1371/journal.pgph.0003134. eCollection 2024.
6
HIV counseling, testing, and test result receipt among East African women of reproductive age using recent national health surveys.
Front Reprod Health. 2024 Feb 7;6:1305671. doi: 10.3389/frph.2024.1305671. eCollection 2024.
7
HIV programme sustainability in Southern and Eastern Africa and the changing role of external assistance for health.
Health Policy Plan. 2024 Jan 23;39(Supplement_1):i107-i117. doi: 10.1093/heapol/czad091.
8
HIV-exposed uninfected infants' immune defects: From pathogen sensing, oxidative burst to antigens responses.
iScience. 2023 Nov 10;26(12):108427. doi: 10.1016/j.isci.2023.108427. eCollection 2023 Dec 15.
9
Stakeholder perspectives on interventions to improve HIV pre-exposure prophylaxis uptake and continuation in Lesotho: A participant-ranked preferences study.
PLOS Glob Public Health. 2023 Sep 27;3(9):e0001423. doi: 10.1371/journal.pgph.0001423. eCollection 2023.
10
HIV and AIDS prevention: knowledge, attitudes, practices and health literacy of older persons in the Western Cape and KwaZulu-Natal Provinces, South Africa and in Lesotho.
BMC Geriatr. 2023 May 8;23(1):279. doi: 10.1186/s12877-023-04009-7.
本文引用的文献
1
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7.
2
Evaluation of large-scale combination HIV prevention programs: essential issues.
J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):e23-8. doi: 10.1097/QAI.0b013e318227af37.
3
The Demand for, and Impact of, Learning HIV Status.
Am Econ Rev. 2008 Dec 1;98(5):1829-1863. doi: 10.1257/aer.98.5.1829.
4
HIV-1 treatment as prevention: the good, the bad, and the challenges.
Curr Opin HIV AIDS. 2011 Jul;6(4):315-25. doi: 10.1097/COH.0b013e32834788e7.
5
Towards an improved investment approach for an effective response to HIV/AIDS.
Lancet. 2011 Jun 11;377(9782):2031-41. doi: 10.1016/S0140-6736(11)60702-2.
6
Acute HIV-1 Infection.
N Engl J Med. 2011 May 19;364(20):1943-54. doi: 10.1056/NEJMra1011874.
7
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study.
Lancet Infect Dis. 2011 Jul;11(7):525-32. doi: 10.1016/S1473-3099(11)70060-3. Epub 2011 May 3.
8
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.
J Virol. 2011 Jul;85(14):7029-36. doi: 10.1128/JVI.00171-11. Epub 2011 May 4.
9
Uptake of biomedical interventions for prevention of sexually transmitted HIV.
Curr Opin HIV AIDS. 2011 Mar;6(2):114-8. doi: 10.1097/COH.0b013e328343ad7e.
10
The future of HIV testing.
J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2:S102-5. doi: 10.1097/QAI.0b013e3181fbca44.
Zotero 插件